Full-Time

Associate Engineering Fellow - Process Knowledge and Data Architecture

Updated on 9/3/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$154.4k - $242.6k/yr

+ Short-term incentives + Long-term incentives + 401(k) company match

Cambridge, MA, USA

In Person

May require approximately 10% travel.

Bachelor's, Master's, PhD

Category
Data & Analytics (1)
Required Skills
Microsoft Azure
Data Visualization
Data Science
Machine Learning
Data Engineering
AWS
Data Modeling
Data Governance
Data Analysis

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A PhD in Chemical Engineering, Chemistry, Data Science, or a related field with at least 7 years of relevant experience; an MS with at least 13 years; or a BS with at least 15 years.
  • Strong expertise in data architecture, data modeling, and data integration, preferably within pharmaceutical research and development or manufacturing environments.
  • Experience working with scientific data systems such as Electronic Lab Notebooks, Laboratory Information Management Systems, and Manufacturing Execution Systems, and integrating laboratory and manufacturing datasets.
  • Proven experience designing scalable data platforms and pipelines, including cloud-based architectures such as Amazon Web Services or Azure and modern data stacks.
  • Strong understanding of data governance, metadata management, and FAIR data principles.
  • Experience enabling analytics, modeling, or artificial intelligence and machine learning applications through structured data frameworks.
  • Understanding of pharmaceutical process development or manufacturing workflows, including Chemistry, Manufacturing, and Controls and current Good Manufacturing Practice considerations.
  • Demonstrated ability to work in cross-functional, matrix environments and influence stakeholders across scientific and technical domains.
  • Strong communication skills, with the ability to translate complex technical concepts into actionable insights for diverse audiences.
  • Analytical and problem-solving skills to troubleshoot critical issues, determine causes, and identify possible solutions.
  • Ability to work effectively on global cross-functional teams.
  • Ability to communicate clearly and concisely, document issues and concerns, adjust communication style for the audience, communicate effectively with senior management, and support technical authorship and approval of internal documents.
  • Subject matter expertise in one or more specific scientific areas and demonstrated ability to contribute across multiple scientific endeavors.
  • Ability to capture organizational knowledge and improve solutions, processes, and deliverables through the use and sharing of information.
  • Project management skills and ability to manage time and internal and external resources, including vendors.
  • Demonstrated involvement in the professional community through scientific posters or lectures at professional conferences or events.
  • Ability to influence and guide others toward department or function goals and objectives.
Responsibilities
  • Lead the design, governance, and lifecycle management of structured reaction, process, vessel, and material databases to establish a unified and reusable process knowledge layer.
  • Design, implement, and govern integrated data architectures linking chemistry, process parameters, scale, equipment attributes, and analytical results across laboratory and manufacturing environments, including Electronic Lab Notebooks, Laboratory Information Management Systems, Process Analytical Technology, and Manufacturing Execution Systems.
  • Build and maintain scalable data pipelines that transform laboratory and manufacturing data into reusable assets for mechanistic modeling, digital twins, and artificial intelligence and machine learning applications.
  • Define metadata models, ontologies, and data standards; enable Electronic Lab Notebook, Process Analytical Technology, and technology data platform ingestion pipelines; and implement FAIR data principles.
  • Establish and enforce data governance frameworks that ensure data quality, traceability, auditability, and lifecycle controls aligned with regulatory expectations such as current Good Manufacturing Practice and data integrity.
  • Integrate disparate data sources and systems to eliminate silos and enable a single source of truth across process development workflows.
  • Collaborate with Process Development, Modeling, Automation, and Engineering teams to ensure data supports advanced analytics, modeling, and decision-making.
  • Translate process development needs into data architecture and platform requirements and work with IT, data engineering, and digital teams to implement scalable, secure, and compliant solutions.
  • Develop data access, visualization, and reporting capabilities such as dashboards to support project teams and leadership in making informed decisions.
  • Support the selection, deployment, and integration of digital platforms such as cloud environments, data lakes, and application programming interfaces.
  • Define the connected data and model roadmap, identify architecture gaps, and partner with IT and Digital teams to ensure interoperability and long-term platform sustainability.
  • Define model standards, validation frameworks, version control, and lifecycle management for predictive and hybrid models deployed across development and manufacturing.
  • Promote data management, standards, and reuse best practices and train and support scientists and engineers in adopting digital tools and workflows.
  • Stay informed about industry trends, emerging technologies, and regulatory expectations to continuously evolve data and knowledge capabilities.
  • Influence and align cross-functional stakeholders to deliver integrated data solutions without direct authority.
  • Identify vendors and build relationships to obtain technologies needed to deliver against goals.
  • Manage key vendor relationships across multiple projects and proactively resolve vendor issues.
  • Represent Takeda and participate in pre-competitive collaborations with academic and industrial partners.
  • Author relevant sections of regulatory documents, reports, and peer-reviewed manuscripts.
  • Travel approximately 10% as required.
Desired Qualifications
  • Experience with ontologies, knowledge graphs, or semantic data models.
  • Experience supporting digital twins, advanced process control, or hybrid modeling.
  • A track record of driving enterprise data initiatives or platform deployments.
  • Experience with regulatory data integrity requirements such as ALCOA+.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.